U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: Evidence for functional relevance

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Rademacher, David J ^a   Patel, Sachin ^a   Ho, W S Vanessa ^a   Savoie, Amanda M ^a   Rusch, Nancy J ^a   Gauthier, Kathryn M ^a   Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 arachidonylglycerol; AM 251; Cannabinoids; CB1 receptor; Mass spectrometry; N arachidonylethanolamine; SR 141716

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; N ARACHIDONYLETHANOLAMINE; RIMONABANT; SEROTONIN; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY TONE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEEDBACK SYSTEM; MALE; MIDDLE CEREBRAL ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ANTERIOR CEREBRAL ARTERY; DIGLYCERIDES; ENDOCANNABINOIDS; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHATIDYLETHANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VASOCONSTRICTOR AGENTS;

EID: 19344367770     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00978.2004     Document Type: Article

References (55)

1. Ashton JC, Appleton I, Darlington CL, and Smith PF. Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol 44: 517-519, 2004.
2. Berdyshev EV, Schmid PC, Krebsbach RJ, and Schmid HH. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 15: 2171-2178, 2001.
3. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, and Schmid HHO. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88: 1159-1167, 2004.
4. Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le Fur G, and Casellas P. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 270: 13973-13980, 1995.
5. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, and Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330-22339, 1997.
6. Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA, Shohami E, Mechoulam R, and Spatz M. Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 87: 323-327, 2000.
7. Deutsch D and Chin S. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791-796, 1993.
8. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, and Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100: 1538-1546, 1997.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
10. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, and Piomelli D. Formation and inactivation of endogenous cannabi-noid anandamide in central neurons. Nature 372: 686-691, 1994.
11. Dorn GW, 2nd Becker MW, and Davis MG. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 267: 24897-24905, 1992.
12. Egertova M, Giang DK, Cravatt BF, and Elphick MR. A new perspec-tive on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci 265: 2081-2085, 1998.
13. Ellis EF, Moore SF, and Willoughby KA. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol Heart Circ Physiol 269: H1859-H1864, 1995.
14. Florian JA and Watts SW. Integration of mitogen-activated protein kinase kinase activation in vascular 5-hydroxytryptamine 2A receptor signal transduction. J Pharmacol Exp Ther 284: 346-355, 1998.
15. Freund TF, Katona I, and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066, 2003.
16. Gauthier-Rein KM, Bizub DM, Lombard JH, and Rusch NJ. Hypoxia-induced hyperpolarization is not associated with vasodilation of bovine coronary resistance arteries. Am J Physiol Heart Circ Physiol 272: H1462-H1469, 1997.
17. 2+ channel current. Am J Physiol Heart Circ Physiol 276: H2085-H2093, 1999.
18. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, and Spatz M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92, 2004.
19. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, and Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954: 73-81, 2002.
20. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 61: 3-18, 2000.
21. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther 294: 1-6, 2000.
22. Hillard CJ, Edgemond WS, and Campbell WB. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem 64: 677-683, 1995.
23. Hillard CJ, Wilkison DM, Edgemond WS, and Campbell WB. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1257: 249-256, 1995.
24. Jackson WF, Huebner JM, and Rusch NJ. Enzymatic isolation and characterization of single vascular smooth muscle cells from cremasteric arterioles. Microcirculation 4: 35-50, 1997.
25. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141, 1999.
26. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, and Hillard CJ. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 72: 2379-2387, 1999.
27. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, and Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769-776, 1999.
28. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, and Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840, 2000.
29. Marin J, Salaices M, Gomez B, and Lluch S. Noradrenergic component in the vasoconstriction induced by 5-hydroxytryptamine in goat cerebral arteries. J Pharm Pharmacol 33: 715-719, 1981.
30. Mathew R, Wilson W, Humphreys D, Lowe J, and Wiethe K. Changes in middle cerebral artery velocity after marijuana. Biol Psychiatry 32: 164-169, 1992.
31. Mathew RJ and Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci 52: 757-767, 1993.
32. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90, 1995.
33. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, and Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362: R1-R3, 1998.
34. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, and Hillard CJ. Anandamide content is increased and CB(1) cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129: 743-750, 2004.
35. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, and Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995, 1999.
36. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, and Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705, 2003.
37. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, and Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531, 2001.
38. Parmentier-Batteur S, Jin K, Mao XO, Xie L, and Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22: 9771-9775, 2002.
39. Parsons AA, Whalley ET, Feniuk W, Connor HE, and Humphrey PP. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol 96: 434-440, 1989.
40. Patel S, Rademacher DJ, and Hillard CJ. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306: 880-888, 2003
41. Pestonjamasp VK and Burstein SH. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1394: 249-260, 1998.
42. Pletscher A. Release of endogenous noradrenaline and 5-hydroxytryptamine from human blood platelets by thrombin. J Pharm Pharmacol 33: 669-670, 1981.
43. Pratt PF, Hillard CJ, Edgemond WS, and Campbell WB. N- arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol Heart Circ Physiol 274: H375-H381, 1998.
44. Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, and Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67: 1381-1387, 2004.
45. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, and Vetter H. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 26: 771-780, 1995.
46. Savinainen JR, Jarvinen T, Laine K, and Laitinen JT. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134: 664-672, 2001.
47. Schror K. Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia. Eur Heart J 11, Suppl B: 27-34, 1990.
48. Stella N, Schweitzer P, and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778, 1997.
49. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, and Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 243: 838-843, 1998.
50. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97, 1995.
51. von Holst H, Granstrom E, Hammarstrom S, Samuelsson B, and Steiner L. Effect of leucotrienes C4, D4, prostacyclin and thromboxane A2 on isolated human cerebral arteries. Acta Neurochir (Wien) 62: 177-185, 1982.
52. Wagner JA, Jarai Z, Batkai S, and Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203-210, 2001.
53. Wagner JA, Varga K, Jarai Z, and Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434, 1999.
54. Walter L, Franklin A, Witting A, Moller T, and Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277: 20869-20876, 2002.
55. Wang Y, Baimbridge KG, and Mathers DA. Effect of serotonin on intracellular free calcium of rat cerebrovascular smooth muscle cells in culture. Can J Physiol Pharmacol 69: 393-399, 1991.